A Viral Ubiquitin Ligase Has Substrate Preferential SUMO Targeted Ubiquitin Ligase Activity that Counteracts Intrinsic Antiviral Defence

English version České info

Intrinsic antiviral resistance represents the first line of intracellular defence against virus infection. During herpes simplex virus type-1 (HSV-1) infection this response can lead to the repression of viral gene expression but is counteracted by the viral ubiquitin ligase ICP0. Here we address the mechanisms by which ICP0 overcomes this antiviral response. We report that ICP0 induces the widespread proteasome-dependent degradation of SUMO-conjugated proteins during infection and has properties related to those of cellular SUMO-targeted ubiquitin ligases (STUbLs). Mutation of putative SUMO interaction motifs within ICP0 not only affects its ability to degrade SUMO conjugates, but also its capacity to stimulate HSV-1 lytic infection and reactivation from quiescence. We demonstrate that in the absence of this viral countermeasure the SUMO conjugation pathway plays an important role in mediating intrinsic antiviral resistance and the repression of HSV-1 infection. Using PML as a model substrate, we found that whilst ICP0 preferentially targets SUMO-modified isoforms of PML for degradation, it also induces the degradation of PML isoform I in a SUMO modification-independent manner. PML was degraded by ICP0 more rapidly than the bulk of SUMO-modified proteins in general, implying that the identity of a SUMO-modified protein, as well as the presence of SUMO modification, is involved in ICP0 targeting. We conclude that ICP0 has dual targeting mechanisms involving both SUMO- and substrate-dependent targeting specificities in order to counteract intrinsic antiviral resistance to HSV-1 infection.

Vyšlo v časopise: A Viral Ubiquitin Ligase Has Substrate Preferential SUMO Targeted Ubiquitin Ligase Activity that Counteracts Intrinsic Antiviral Defence. PLoS Pathog 7(9): e32767. doi:10.1371/journal.ppat.1002245
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002245

Souhrn

Zdroje

1. RandowFLehnerPJ 2009 Viral avoidance and exploitation of the ubiquitin system. Nat Cell Biol 11 527 534

2. EverettRD 2006b The roles of ICP0 during HSV-1 infection. Alpha herpesviruses: molecular and cellular biology Sandri-GoldinRM Wymondham, United Kingdom Caister Academic Press 39 64

3. BoutellCSadisSEverettRD 2002 Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J Virol 76 841 850

4. LiumEKSilversteinS 1997 Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential alpha27 gene. J Virol 71 8602 8614

5. EverettRD 1987 A detailed mutational analysis of Vmw110, a trans-acting transcriptional activator encoded by herpes simplex virus type 1. Embo J 6 2069 2076

6. EverettRO'HarePO'RourkeDBarlowPOrrA 1995 Point mutations in the herpes simplex virus type 1 Vmw110 RING finger helix affect activation of gene expression, viral growth, and interaction with PML-containing nuclear structures. J Virol 69 7339 7344

7. O'RourkeDElliottGPapworthMEverettRO'HareP 1998 Examination of determinants for intranuclear localization and transactivation within the RING finger of herpes simplex virus type 1 IE110k protein. J Gen Virol 79 (Pt 3) 537 548

8. EverettRDParsyMLOrrA 2009 Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes. J Virol 83 4963 4977

9. EverettRDFreemontPSaitohHDassoMOrrA 1998 The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J Virol 72 6581 6591

10. Chelbi-AlixMKde TheH 1999 Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins. Oncogene 18 935 941

11. MullerSDejeanA 1999 Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J Virol 73 5137 5143

12. EverettRDRechterSPapiorPTavalaiNStammingerT 2006 PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 80 7995 8005

13. EverettRDParadaCGriponPSirmaHOrrA 2008 Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J Virol 82 2661 2672

14. EverettRDChelbi-AlixMK 2007 PML and PML nuclear bodies: Implications in antiviral defence. Biochimie 89 819 830

15. EverettRDMurrayJ 2005 ND10 Components Relocate to Sites Associated with Herpes Simplex Virus Type 1 Nucleoprotein Complexes during Virus Infection. J Virol 79 5078 5089

16. EverettRDMurrayJOrrAPrestonCM 2007 Herpes Simplex Virus Type 1 Genomes Are Associated with ND10 Nuclear Substructures in Quiescently Infected Human Fibroblasts. J Virol 81 10991 11004

17. Cuchet-LourençoDBoutellCLukashchukVGrantKSykesA 2011 SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog, 7 e1002123

18. XieYKerscherOKroetzMBMcConchieHFSungP 2007 The yeast Hex3.Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J Biol Chem 282 34176 34184

19. UzunovaKGottscheKMitevaMWeisshaarSRGlanemannC 2007 Ubiquitin-dependent proteolytic control of SUMO conjugates. J Biol Chem 282 34167 34175

20. PruddenJPebernardSRaffaGSlavinDAPerryJJ 2007 SUMO-targeted ubiquitin ligases in genome stability. Embo J 26 4089 4101

21. SunHLeversonJDHunterT 2007 Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. Embo J 26 4102 4112

22. TathamMHGeoffroyMCShenLPlechanovovaAHattersleyN 2008 RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 10 538 546

23. Lallemand-BreitenbachVJeanneMBenhendaSNasrRLeiM 2008 Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10 547 555

24. SongJDurrinLKWilkinsonTAKrontirisTGChenY 2004 Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci U S A 101 14373 14378

25. SongJZhangZHuWChenY 2005 Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif: a reversal of the bound orientation. J Biol Chem 280 40122 40129

26. HeckerCMRabillerMHaglundKBayerPDikicI 2006 Specification of SUMO1- and SUMO2-interacting motifs. J Biol Chem 281 16117 16127

27. StehmeierPMullerS 2009 Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell 33 400 409

28. KerscherO 2007 SUMO junction-what's your function? New insights through SUMO-interacting motifs. EMBO Rep 8 550 555

29. WeisshaarSRKeusekottenKKrauseAHorstCSpringerHM 2008 Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML. FEBS Lett 582 3174 3178

30. GeoffroyMCJaffrayEGWalkerKJHayRT 2010 Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell 21 4227 4239

31. LukashchukVEverettRD 2010 Regulation of ICP0-null mutant herpes simplex virus type 1 infection by ND10 components ATRX and hDaxx. J Virol 84 4026 4040

32. HayashiTSekiMMaedaDWangWKawabeY 2002 Ubc9 is essential for viability of higher eukaryotic cells. Exp Cell Res 280 212 221

33. DassoM 2008 Emerging roles of the SUMO pathway in mitosis. Cell Div 3 5

34. ZhangXDGoeresJZhangHYenTJPorterAC 2008 SUMO-2/3 modification and binding regulate the association of CENP-E with kinetochores and progression through mitosis. Mol Cell 29 729 741

35. BaileyDO'HareP 2002 Herpes simplex virus 1 ICP0 co-localizes with a SUMO-specific protease. J Gen Virol 83 2951 2964

36. Boyer-GuittautMBirsoyKPotelCElliottGJaffrayE 2005 SUMO-1 modification of human transcription factor (TF) IID complex subunits: inhibition of TFIID promoter-binding activity through SUMO-1 modification of hsTAF5. J Biol Chem 280 9937 9945

37. MullenJRBrillSJ 2008 Activation of the Slx5-Slx8 ubiquitin ligase by poly-small ubiquitin-like modifier conjugates. J Biol Chem 283 19912 19921

38. LinDYHuangYSJengJCKuoHYChangCC 2006 Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell 24 341 354

39. BerndtAHofmann-WinklerHTavalaiNHahnGStammingerT 2009 Importance of covalent and noncovalent SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for viral infection. J Virol 83 12881 12894

40. BoutellCEverettRHilliardJSchafferPOrrA 2008 Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner. J Virol 82 10647 10656

41. DavidoDJvon ZagorskiWFLaneWSSchafferPA 2005 Phosphorylation site mutations affect herpes simplex virus type 1 ICP0 function. J Virol 79 1232 1243

42. EverettRDMeredithMOrrACrossAKathoriaM 1997 A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. Embo J 16 1519 1530

43. LilleyCEChaurushiyaMSBoutellCLandrySSuhJ 2010 A viral E3 ligase targets RNF8 and RNF168 to control histone ubiquitination and DNA damage responses. EMBO J 29 943 955

44. ShenTHLinHKScaglioniPPYungTMPandolfiPP 2006 The mechanisms of PML-nuclear body formation. Mol Cell 24 331 339

45. JensenKShielsCFreemontPS 2001 PML protein isoforms and the RBCC/TRIM motif. Oncogene 20 7223 7233

46. CuchetDSykesANicolasAOrrAMurrayJ 2011 PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication. J Cell Sci 124 280 291

47. KamitaniTKitoKNguyenHPWadaHFukuda-KamitaniT 1998 Identification of three major sentrinization sites in PML. J Biol Chem 273 26675 26682

48. EverettRDBoutellCMcNairCGrantLOrrA 2010 Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins. J Virol 84 3476 3487

49. WangLOliverSSommerMRajamaniJReicheltM 2011 Disruption of PML Nuclear Bodies is Mediated by ORF61 SUMO-interacting Motifs and Required for Varicella-Zoster Virus Pathogenesis in Skin. PLoS Pathog 7 In Press

50. UlrichHD 2008 The fast-growing business of SUMO chains. Mol Cell 32 301 305

51. BieniaszPD 2004 Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 5 1109 1115

52. TavalaiNStammingerT 2010 Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Res 157 128 133

53. HayRT 2005 SUMO: a history of modification. Mol Cell 18 1 12

54. SeelerJSMarchioALossonRDesterroJMHayRT 2001 Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol Cell Biol 21 3314 3324

55. GuHRoizmanB 2009 The two functions of herpes simplex virus 1 ICP0, inhibition of silencing by the CoREST/REST/HDAC complex and degradation of PML, are executed in tandem. J Virol 83 181 187

56. MeredithMOrrAElliottMEverettR 1995 Separation of sequence requirements for HSV-1 Vmw110 multimerisation and interaction with a 135-kDa cellular protein. Virology 209 174 187

57. BoutellCCanningMOrrAEverettRD 2005 Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. J Virol 79 12342 12354

58. BoutellCEverettRD 2003 The Herpes Simplex Virus Type 1 (HSV-1) Regulatory Protein ICP0 Interacts with and Ubiquitinates p53. J Biol Chem 278 36596 36602

59. HuangTTWuerzberger-DavisSMWuZHMiyamotoS 2003 Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115 565 576

60. HayRT 2004 Modifying NEMO. Nat Cell Biol 6 89 91

61. MorrisJRBoutellCKepplerMDenshamRWeekesD 2009 The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 462 886 890

62. GalantyYBelotserkovskayaRCoatesJPoloSMillerKM 2009 Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks. Nature 462 935 939

63. BoggioRColomboRHayRTDraettaGFChioccaS 2004 A mechanism for inhibiting the SUMO pathway. Mol Cell 16 549 561

64. RibetDHamonMGouinENahoriMAImpensF 2010 Listeria monocytogenes impairs SUMOylation for efficient infection. Nature 464 1192 1195

65. GriponPRuminSUrbanSLe SeyecJGlaiseD 2002 Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99 15655 15660

66. StowNDStowEC 1986 Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. J Gen Virol 67 2571 2585

67. EverettRD 1989 Construction and characterization of herpes simplex virus type 1 mutants with defined lesions in immediate early gene 1. J Gen Virol 70 1185 1202

68. EverettRDBoutellCOrrA 2004 Phenotype of a herpes simplex virus type 1 mutant that fails to express immediate-early regulatory protein ICP0. J Virol 78 1763 1774

69. EverettRDCrossAOrrA 1993 A truncated form of herpes simplex virus type 1 immediate-early protein Vmw110 is expressed in a cell type dependent manner. Virology 197 751 756

70. SchenkPLudwigH 1988 The 65 K DNA binding protein appears early in HSV-1 replication. Arch Virol 102 119 123

71. ShowalterSDZweigMHamparB 1981 Monoclonal antibodies to herpes simplex virus type 1 proteins, including the immediate-early protein ICP 4. Infect Immun 34 684 692

72. StuurmanNde GraafAFlooreAJossoAHumbelB 1992 A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies. J Cell Sci 101 773 784

73. SternsdorfTJensenKWillH 1997 Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol 139 1621 1634

74. HofmannHSindreHStammingerT 2002 Functional interaction between the pp71 protein of human cytomegalovirus and the PML-interacting protein human Daxx. J Virol 76 5769 5783